CLINICAL ROLE -
Early View of Ampyra and Gilenya Use by MS Patients
Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.
Read More
2010 Drug Utilization and Cost Trends for Antidiabetic Agents
The antihyperglycemic therapeutic class will continue to be a major contributor to prescription drug trends in 2011 and beyond.
AAN 2025: Paving the Way for Precision Medicine in Alzheimer, Neurodegenerative Diseases
Study Reveals Low RSV Knowledge and Vaccine Uptake Among Hospitalized Older Adults
MANIFEST-2 Study: Pelabresib Plus Ruxolitinib Is Superior to JAK Inhibitors Alone
How Microbial Preservation Supports Quality and Safety in Compounding Pharmacies